Join Growin Stock Community!

Zhengye biotechnology holding limitedZYBT.US Overview

US StockHealthcare
(No presentation for ZYBT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ZYBT AI Insights

ZYBT Overall Performance

ZYBT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ZYBT Recent Performance

-2.38%

Zhengye biotechnology holding limited

0.05%

Avg of Sector

-0.31%

S&P500

ZYBT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ZYBT Key Information

ZYBT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ZYBT Profile

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

Price of ZYBT

ZYBT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ZYBT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.25
PB Ratio
0.88
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.25
PB Ratio
0.88
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ZYBT's latest earnings report released?

    The most recent financial report for Zhengye biotechnology holding limited (ZYBT) covers the period of 2023Q4 and was published on 2023/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ZYBT's short-term business performance and financial health. For the latest updates on ZYBT's earnings releases, visit this page regularly.

  • How much debt does ZYBT have?

    As of the end of the reporting period, Zhengye biotechnology holding limited (ZYBT) had total debt of 86.43M, with a debt ratio of 0.18. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ZYBT have?

    At the end of the period, Zhengye biotechnology holding limited (ZYBT) held Total Cash and Cash Equivalents of 18.6M, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.